Skip to main content

Table 4 Governments in the WHO European region reporting activities addressing viral hepatitis by WHO Global Hepatitis Programme strategic axis and EU/EFTA membership (N=44)

From: Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey

   Non EU/EFTA n=16 (%) EU/EFTA n=28 (%) P-value
National coordination Have viral hepatitis programme activities address PWID as a specific population 10 (63) 22 (79) 0.512
  Have a written national viral hepatitis prevention & control strategy which also targets ID use 6 (38) 6 (21) 0.335
Axis 1 Held events for World Hepatitis Day 2012 7 (44) 10 (36) 0.765
  Funded viral hepatitis awareness campaigns focusing on harm reduction for PWID (other than World Hepatitis Day) 5 (31) 5 (18) 0.404
Axis 2 Conduct regular serosurveys among PWID 6 (38) 6 (21) 0.639
Axis 3 Have a national policy for prevention & control of viral hepatitis among PWID 9 (56) 16 (57) 0.954
Axis 4 Have HBV & HCV testing which is:    
  • Free of charge for all 6 (38) 14 (50) 0.569
  • Free of charge for PWID 2 (13) 4 (14) 0.423
  Have publicly funded treatment for HBV 9 (56) 27 (96) 0.004*
  HBV Drugs on national essential medicines list or subsidized by government:    
  • Interferon alpha 12 (75) 22 (79) 0.786
  • Pegylated interferon 11 (69) 22 (79) 0.469
  • Lamivudine 13 (81) 24 (86) 0.697
  • Adefovir dipivoxil 4 (25) 20 (71) 0.003*
  • Entecavir 3 (20) 19 (68) 0.002*
  • Telbivudine 4 (25) 13 (46) 0.160
  • Tenofovir 8 (50) 19 (68) 0.242
  Have publicly funded treatment for HCV 9 (56) 26 (93) 0.010*
  HCV Drugs on national essential medicines list or subsidized by government:    
  • Interferon alpha 8 (50) 22 (79) 0.050*
  • Pegylated interferon 12 (75) 23 (82) 0.572
  • Ribavirin 14 (88) 24 (86) 0.868
  • Boceprevir 2 (13) 15 (54) 0.007*
  • Telaprevir 3 (19) 14 (50) 0.041*